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ABSTRAK
Tujuan: mengembangkan model prediksi kanker prostat berdasarkan populasi Indonesia. Metode: kami 
mengikutsertakan seluruh pasien pembesaran prostat jinak (BPH) dan kanker prostat yang menjalani biopsi 
prostat dan prostatektomi pada Januari 2009 dan Desember 2013 dari 5 pusat urologi di Indonesia. Setelah itu, 
dicari hubungan antara kemungkinan kanker prostat dengan berbagai variabel, seperti: umur, nilai PSA, volume 
prostat (menggunakan pemeriksaan ultrasonografi transabdominal atau transrektal), dan pemeriksaan colok dubur. 
Kami menghitung persamaan skor prediktif untuk memprediksi terjadinya kanker prostat menggunakan analisis 
chi-square, uji Kolmogorov-Smirnov, regresi logistik multipel, dan kurva ROC. Selanjutnya kami mendesain suatu 
aplikasi untuk memprediksi risiko kanker prostat yang dinamakan Indonesian Prostate Cancer Risk Calculator 
(IPCRC). Hasil: terdapat 784 pasien kanker prostat dan 1.173 pasien BPH yang digunakan dalam pengembangan 
kalkulator risiko ini. Rata-rata umur adalah 66,9±8,1 tahun; PSA adalah 72,4±248,9 ng/ml; dan volume prostat 
adalah 49,6±28,2 ml. Pemeriksaan colok dubur yang abnormal ditemukan pada 637 pasien kanker prostat dan 
56 pasien BPH. Kami mengikutsertakan umur, nilai PSA, hasil pemeriksaan colok dubur yang abnormal dalam 
analisis dan didapatkan hasil yang bermakna dengan nilai p<0,05 pada model univariat. Walaupun tidak bermakna, 
kami juga menyertakan volume prostat (p=0,157) karena kepentingan klinisnya. Analisis ROC menunjukkan nilai 
AUC sebesar 0,935; sensitivitas sebesar 90,1%; dan spesifisitas sebesar 80% dalam memprediksi kanker prostat 
pada populasi indonesia. Kesimpulan: pengembangan Indonesian Prostate Cancer Risk Calculator (IPCRC) 
mengikutsertakan umur, nilai PSA, pemeriksaan colok dubur, dan volume prostat sebagai variabel-variabelnya. 
Kedepannya, dibutuhkan studi prospektif untuk memvalidasi kalkulator risiko ini.
Kata kunci: kanker prostat, kalkulator risiko, deteksi dini.
Prahara Yuri                                                                                                          Acta Med Indones-Indones J Intern Med
96
ABSTRACT
Aim: to develop a prediction risk model of prostate cancer  based on Indonesia population. Methods: we 
included all benign prostate hyperthrophy (BPH) and PCa patients who had prostate biopsy and prostatectomy 
between January 2009 and December 2013 from 5 urology centers in Indonesia. The relationship between the 
possibility of PCa with the following variables including: age; PSA level, prostate volume (by transabdominal 
ultrasound or transrectal ultrasound) and digital rectal examination (DRE) finding. We calculated a predictive 
scoring equation to predict the possibility of PCa using chi-square analysis, Kolmogorov-Smirnov test, multiple 
logistic regression and ROC curve. Then, we designed an application for predicting prostate cancer risk called 
Indonesian Prostate Cancer Risk Calculator (IPCRC). Results: there were 784 PCa and 1173 BPH patients 
were used for developing the risk calculator in our study. The mean ages, PSA and prostate volume are 66.9±8.1 
years old; 72.4±248.9 ng/ml and 49.6±28.2 ml, respectively. Abnormal DRE was found in 637 PCa and 56 
BPH. We included age, PSA level, abnormal DRE finding (all showed significant p<0.05 in univariate model). 
Additionally, although not significant, we included prostate volume (p=0.157) due to its clinical importance. The 
corrected ROC analysis showed AUC 0.935, sensitivity of 90.1% and specificity 80% in predicting the prostate 
cancer in our population. Conclusion: we have developed the Indonesian Prostate Cancer Risk Calculator 
which includes age, PSA, DRE, and prostate volume as its variables. Future prospective study to validate the 
risk calculator is needed.
Key words: prostate cancer, risk calculator, early detection.
INTRODUCTION
Prostate cancer (PCa) is the second most 
frequently diagnosed cancer and the sixth leading 
cause of cancer death in men worldwide. It was 
estimated 914,000 new cases were found and 
responsible for 6% (258 400) of total cancer 
deaths in men in 2008.1-3 Unlike in westem 
countries, PCa is relatively rare in Indonesia.4 
Indonesian Society of Urologic Oncology 
(ISUO) in the period 2006-2010  reported 971 
PCa cases in Indonesia with the mean of age 68.3 
years and PCa was found in 563 (57.9%) cases 
by prostate biopsy.5
Since 30 years ago, considerable knowledge 
has been gained for finding the factors that 
may identify a low or high risk of PCa with 
opportunistic screening. The discovery of prostate 
specific antigen (PSA) was a cornerstone finding 
to develop many strategies to detect PCa.6 Since 
the introduction of PSA testing in 1987, serum 
PSA has become a useful tool in screening for 
PCa. However, it is still difficult to differentiate 
prostate cancer from benign prostatic disease 
since PSA levels depend on age, prostate size, 
and the inflammatory state of the prostate. In 
addition to total PSA, there are other clinical 
factors that improve the detection rate of prostate 
cancer, such as age, digital rectal examination 
(DRE) findings, transrectal ultrasound (TRUS) 
findings, PSA density (PSAD), PSA velocity, 
PSAD of transition zone volume (PSADT), 
percent of free PSA (% free PSA), and age-
specific PSA.7 Serum prostate-specific antigen 
(PSA) screening for PCa is controversial because 
the test lacks specificity and therefore can induce 
many unnecessary prostate biopsies and lead to 
overdiagnosis of PCa.8 This disadvantage can 
be reduced by using individual risk estimation.9 
In the last decade, several nomograms and 
artificial neural networks have been developed 
to predict prostate cancer, either on initial or 
repeat biopsy. In general, these models have 
been based on PSA values, a DRE and age, but 
have also used other variables, including race, 
family history, year of biopsy, prostate volume, 
number of needle cores, percentage free PSA 
(% fPSA), number of previous negative biopsies 
and PSA velocity.10 Among prediction tools, 
nomograms provide superior, individualized, 
disease-related risk estimations that facilitate 
management-related decisions. The ability of 
the nomograms to predict PCa diagnosis, stage, 
and prognosis has been confirmed. In general, 
it has been demonstrated that these predictive 
models perform better than clinical judgment 
when predicting probabilities of outcome.11
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In recent years, several nomograms have 
become available to the clinician, assisting in 
the risk stratification of prostate cancer (PCa) at 
needle biopsy.12 The Prostate Cancer Prevention 
Trial – Risk Calculator (PCPT-RC) was one of 
the first online tools to revolutionize the approach 
to predicting PCa and the newest The European 
Randomized Study of Screening Prostate Cancer 
(ERSPC) Risk Calculator are the best known 
nomograms incorporating known risk factors.2,13 
The Prostate Cancer Prevention Trial (PCPT) 
was developed from 18,882 men in North 
American double-blind randomized study of the 
chemoprevention effects of finasteride versus 
placebo on prostate cancer development.14-17 
The European Randomized Study of Screening 
for Prostate Cancer (ERSPC) risk calculator has 
been developed based on 6,288 men, mostly 
Caucasian, participants in the screening arm 
of ERSPC study.18-20 There are few studies 
investigating the validity of the ERSPC-RC or 
the PCPT-RC in Asians. 
During the period of 3 years (September 
1994-August 1997), Djoko et al.4 reported 344 
cases with prostate symptom without urinary 
retention which consisted of 332 BPH patients 
and 12 PCa patients. With a new cut-off point, 
most patients (69%) had PSA less or same as 8 
ng/ml and none of them had PCa. In intermediate 
PSA level (8.1-30 ng/mL), we found 90 patients, 
with only 1 patient had PCa. In PSA above 
30 ng/ml 11 from 18 patients (61%) had PCa. 
By accepting the recommended western cut-
off levels, there were numerous unnecessary 
biopsies had been done, and the specificity of this 
cut-off was limited (71.9% for PSA less than 4.0 
ng/ml). These data were incomparable to the data 
from western countries.4 This might be due to a 
different our population charateristic related to 
PSA expression. Therefore, we decided to create 
a model that assigns a probability of detecting 
prostate cancer base on age, prostate volume, 
PSA and digital rectal examination (DRE) in 
Indonesian population.1
METHODS
Study Population
In this prognostic study, we included all benign 
prostate hypertrophy (BPH) and PCa patients 
who had prostate biopsy and prostatectomy 
between January 2008 and December 2013 from 
five urology centers (Cipto Mangunkusumo 
Hospital Jakarta, Soetomo Hospital Surabaya, 
Sardjito Hospital Yogyakarta, Hasan Sadikin 
Hospital Bandung and Adam Malik Hospital 
Medan) in Indonesia. Data obtained from 
medical records were age, prostate volume 
measured by trans-abdominal ultrasonography 
(TAUS) or transrectal ultrasonography (TRUS), 
PSA, DRE and histopathological examination. 
Standard forms were used to make the same 
data that collected in each center. We excluded 
patients below 40 years old and volume below 10 
ml. We analyzed 1957 patients who had complete 
medical record data from total of 2577 samples. 
Variables
We chose several factors to evaluate 
the following important predictors for PCa 
predictions, e.g : age, total PSA level, prostate 
volume and DRE findings. PSA was measured 
using PSA Enzyme Immunoassay using PSA 
monoclonal antibody. The prostate was measured 
in three dimensions, and its volume was 
estimated using a modification of the prolate 
ellipsoid formula and recorded in cm3 (0.523 
[length (cm) × width (cm) × height (cm)]) by 
TAUS/TRUS. DRE was classified as normal or 
abnormal (any prostatic nodule or induration). 
The biopsy specimens were examined for the 
presence of cancer and were categorized using 
the Gleason score by a pathologist. All variables 
data were collected from medical record.
Statistical Analysis
The relationship between the possibility of 
prostate cancer and its variables were evaluated. 
The association of each factor with its diagnosis 
was assessed by simple logistic regression 
analysis. Multiple logistic regression analysis 
with backward selection was used to determine 
which factor were independent predictors of PCa 
in the model-building set. A prediction equation 
for prostate cancer prediction was developed 
based on the final logistic regression model. 
We calculated a predictive scoring equation to 
predict the possibility of PCa using chi-square 
analysis, Kolmogorov-Smirnov test, multiple 
logistic regression and receiver operating 
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characteristic (ROC) curve. We regarded a p 
value <0.05 as statistically significant.
The logistic model is as follows;
ln(odds) : β0 + β1(lpsa-lpsac) + β2(lvol-
lvolc) + β3(lage-lagec) + β4(DRE abnormal).
Odds is defined as p/(1–p) where P (in the 
case of this example) is the probability to detect 
prostate cancer. 
In addition, we assessed the performance 
of the final model by internal validation using 
the bootstrap procedure. We generated 1000 
bootstrap samples and draw 1000 random 
sample from the original study population. The 
simple and multiple logistic regression procedure 
was subsequently employed to the validation 
samples. All data analyses were performed with 
SPSS version 20. 
Risk Calculator Application
An android application was made by 
transfering the diagnostic model to a software 
called Microsoft Visual C# 2010. The application 
is called Indonesian prostate cancer risk calculator 
(IPCRC).
RESULTS
In this study, we included 1957 subjects. The 
characteristics of the subjects can be found in 
Table 1. In total, mean of ages, PSA and prostate 
volume are 66.9±8.1 years old; 72.4±248.9 ng/
ml and 49.6±28.2 ml, respectively. Abnormal 
DRE findings were found in less than 45% of the 
patients. Interestingly in Hasan Sadikin hospital, 
less than seven percent of the patients had 
abnormal DRE. Most patients were diagnosed as 
BPH (59.9%). Compared with the others center, 
Cipto Mangunkusumo Jakarta had more patients 
diagnosed with PCa (50.3 %, 232 patients). Their 
mean PSA level was also doubled.
Age, PSA levels and abnormal DRE finding 
showed significant association level with 
the diagnosis (p<0.05) in univariate model. 
Additionally, although not significant, we 
included prostate volume due to its clinical 
importance. Positive weak correlation with PCa 
were shown for age (r=0.045), PSA (r=0.278) and 
prostate volume (p=0.048), while abnormal DRE 
showed strong significant negative correlation 
with diagnosis of Pca (r =- 0.784, p< 0.001). 
(Table 2)
From the logistic regression analysis we 
obtained the model for IPCRC: 
ln(odds) = -1.883 + 0.621 (lpsa - 4.25) + 
0.041(lvol - 5.47) – 1.199 (lage-6.05) + 3,999 
(DRE abnormal). Patient’s risk to get PCa 
increases in younger patients had normal DRE, 
higher PSA and larger prostate volume. BPH 
Table 1. Characteristic of patients in each center
Variables Total (n=1957)
Cipto 
Mangunkusumo
(n=461)
Soetomo
Surabaya
(n=539)
Sardjito
Yogyakarta
(n=266)
Hasan Sadikin 
Bandung
(n=496)
Adam Malik
Medan
(n=200)
Age X±SD 
(Median)
66.9±8.1  
(67)
66.9±7.5  
(67)
64.3±7.8  
(65)
70.1±8.6  
(71)
67.4±8.1  
(68)
68.0±7.4  
(68)
Prostate specific 
antigen (PSA)  
X±SD (Median)
72.4±248.9 
(16.75)
132.2±405.3 
(17.17)
68.6±207.3 
(20.6)
46.1±102.7 
(14.45)
46.6±185.9 
(12.5)
43.7±38.1 
(31.6)
Prostate Volume  
X±SD (Median)
49.6±28.2 
(43.5)
51.1±31.5  
(42.9)
43.9±23.8  
(39)
48.6±32.7 
(43.7)
54.1±27.6 
(53.4)
51.6±23.7 
(45.6)
DRE findings n(%) 
Abnormal
693 (35.4) 211 (45.8) 191 (35.6) 127 (48.1) 33 (6.7) 131 (65.5)
Nodule n(%) 
Positive
553 (28.3) 127 (27.5) 191 (35.6) 119 (45.1) 28 (5.6) 88 (44.2)
Consistency n(%) 
Hard
596 (30.5) 214 (46.4) 191 (35.6) 106 (30.2) 32 (6.5) 53 (26.6)
Diagnosis n(%)
PCa 784 (40.1) 232 (50.3) 224 (41.7) 93 (35.2) 116 (23.4) 119 (59.8)
BPH 1173 (59.9) 229 (49.7) 313 (58.3) 171 (64.8) 380 (76.6) 80 (40.2)
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patients will have a higher score compared to 
Pca patients.
The ROC analysis revealed a sensitivity 
of 90.1% and specificity 80% in predicting the 
prostate cancer in our population with area under 
curve (AUC) of 0.938. In Table 3, we showed 
the callibration of score (in 10 percentiles) to the 
diagnosis. The higher the score percentiles, the 
higher chance diagnosis of Pca were obtained.
Internal Validation
Both bootstrap samples and the random 
sampling set show consistency with the original 
data set. Age, PSA levels and abnormal DRE 
findings showed significant association levels 
with the diagnosis (p<0.05), while prostate 
volume showed the opposite. From the bootstrap 
samples, we got a mean ROC of 0.938, while 
from the random set we got a mean ROC of 
0.941, resulting in optimism corrected ROC of 
0.935. (Figure 1)
Table 2. Bivariate analysis
Variables PCa BPH p value r
Age, X±SD (Median) 67.3±8.6 (68) 66.6±7.7 (67) 0.004* 0.045
Prostate specific antigen (PSA), 
X±SD (Median) 157±377.1 (56) 15.9±19.1 (10) <0.001* 0.278
Prostate volume, X±SD (Median) 51.3±34.2 (43) 48.5±23.4 (44) 0.157* 0.048
DRE findings n(%)  
Abnormal 637 (81.3) 56 (4.8) <0.001# - 0.784$
* Kolmogorov-Smirnov test # Chi square $  significant correlation (p<0.001)
Table 3. Scores accuration with diagnosis (callibration)
Scores (in percentiles)
Diagnosis
Total
BPH CaP
Percentile 10 n 187 8 195
% within scores 95.9 4.1 100.0
Percentile 20 n 179 8 187
% within scores 95.7 4.3 100.0
Percentile 30 n 173 15 188
% within scores 92.0 8.0 100.0
Percentile 40 n 174 32 206
% within scores 84.5 15.5 100.0
Percentile 50 n 194 26 220
% within scores 88.2 11.8 100.0
Percentile 60 n 159 38 197
% within scores 80.7 19.3 100.0
Percentile 70 n 82 112 194
% within scores 42.3 57.7 100.0
Percentile 80 n 20 175 195
% within scores 10.3 89.7 100.0
Percentile 90 n 4 186 190
% within scores 2.1 97.9 100.0
Percentile 100 n 1 184 185
% within scores 0.5 99.5 100.0
Total n 1173 784 1957
% within scores 59.9 40.1 100.0
Figure 1. ROC of Indonesian prostate cancer risk calculator 
(IPCRC)
Indonesian Prostate Cancer Risk Calculator 
(IPCRC)
We showed the display of the application in 
Figure 2A-B. Figure 2A depicts the predictions 
for a 67-yr-old man with a PSA of 2.8 ng/ml 
and a prostate volume of 45.3 cm3. If all the 
other predictors are set on zero, the probability 
of PCa are 2,61%. An abnormal DRE outcome 
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(Figure 2B) would increase this man’s risk for 
PCa to 59.4%.
result of haemodilution. Thus, the interpretation 
of PSA values is prone to error arising from 
nonspecific sources. Furthermore, serum tPSA 
values are poor indicators of the aggressiveness 
of prostate cancer, regardless of the threshold 
chosen. Because PSA does not correlate well 
with aggressiveness, there is a trend in clinical 
practice toward overdiagnosis and consequent 
over-treatment of prostate cancer.22,23 Recently, 
a noninvasive urinary test for the prostate cancer 
gene 3 (PCA3) has been developed. PCA3 is 
an emerging gene-based marker that is highly 
specific for prostate cancer.24,25
In the last 20 years, there has been 
extensive development of predictive tools 
called normogram, which cheap and simple, 
to aid clinicians in predicting PCa diagnosis, 
stage and prognosis. And a number of these risk 
assessment tools are readily available online 
for an individual man to assess his individual 
risk for PCa.6,26 In men with a known PSA, risk 
calculators may hold the promise of identifying 
those who are at increased risk of having PCa and 
are therefore candidates for biopsy.21,24 Therefore, 
it is justifiable in our nomogram to include age, 
PSA, prostate volume and DRE findings.
There were two known common risk 
calculators for screening in the world; ERSPC-
RC and PCPT-RC. ERSPC-RC is a better 
prediction tool of prostate cancer after biopsy 
than the PCPT-RC.2,26 Several studies showed 
that the performance of the PCPT-RC for 
predicting prostate cancer is superior to the 
prediction accuracy of PSA testing alone.3,10,27 
and ERSPC.26 However, in several study, 
PCPT-RC has been shown as  not  universally 
applicable in the population of men with elevated 
PSA (above 3.0 ng/mL).3,12,28 The PCTP-RC 
may overestimate the risk of finding prostate 
cancer.15 This result could be due to that the 
PCPT-RC model was fitted on a  population 
of primarily healthy men with PSA less than 
3.0 ng/mL and above 55 years of age.28,29 The 
accuracy of the PCPTRC on such a healthy 
population of men is not ruled out by the current 
validation study since no cohorts of this type 
were included.15,28
ERSPC selected predictor variables based on 
multivariable analysis including all predictors 
A B
Figure 2. Indonesian prostate cancer risk calculator (IPCRC)
DISCUSSION
In this study, we have developed the 
Indonesian Prostate Cancer Risk Calculator 
using the risk factors variables: age, PSA, DRE, 
and prostate volume of patients. These variables 
were included in the calculator based on data 
from 1957 patients in five urology centers in 
Indonesia. (Figure 2)
General practitioners and urologists are 
increasingly confronted with requests for early 
detection of PCa. Several risk assessment tools 
have been developed to support decision making 
on which diagnostic tools should be conducted 
to screen suspected PCa patient, a PSA test or 
a prostate biopsy.11 However, using PSA for 
screening purposes, may not be suitable since 
the prevalence may be related on individualized 
risk. A limited list of additional risk factors such 
as age, comorbidity, prostate volume, family 
history, ethnicity, digital rectal examination and 
previous biopsy status have been identified to 
modify risk and are important for consideration 
in routine practice.20,21
Characterizing risk based solely on serum 
PSA findings presents inherent difficulties. 
PSA is specific for prostate tissue but not for 
prostate cancer. Elevated values of serum PSA 
are found in many benign conditions involving 
enlargement of the prostate, including BPH 
and acute prostatitis. Conversely, a high body 
mass index erroneously lowers PSA values as a 
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irrespective of statistical significance, whereas 
PCPT included only predictors that were 
statistically significant. It is unclear whether 
models that included all predictor variables were 
overfitted and unstable, potentially increasing 
bias. PCPT and ERSPC did not report calibration 
measures. For model validity assessment, 
internal validation was performed using a 4 to 
10-fold cross-validation for PCPT not ERSPC. 
During development, external validations were 
carried out for both ERSPC and PCPT. All 
studies were reported between 2002 and 2012. 
Countries evaluating the models were mainly 
from North America (Canada and the USA), 
Europe (Austria, Belgium, France, Germany, 
Finland, Italy, The Netherlands, Portugal, and 
Sweden), and Asia (Japan and South Korea). 
In total, PCPT and ERSPC RC3 models 
were validated in 43,072 and 11,536 patients, 
respectively. Reported median ages ranged from 
61-70 years. Overall PSA ranged from 0.1-3210 
ng/mL. The proportion of patients with PCa 
ranged from 21.6-60.7%. In general, ERSPC 
RC3 validation studies reported overestimation 
of PCa risk.30
A study in a Korean population showed 
the PCa was diagnosed in 125 (24.1%) men. 
For prostate cancer prediction, the area under 
curve (AUC) of the ERSPC-RC was 77.4%. 
This result was significantly greater than the 
AUCs of the PCPT-RC and the PSA (64.5% 
and 64.1%, respectively, p<0.01), but not 
significantly different from the AUC of the 
PSA density (PSAD) (76.1%, p=0.540). The 
ERSPC-RC was better than PCPT-RC and PSA 
in predicting prostate cancer risk in the present 
study. However, the difference in performance 
between the ERSPC-RC and PSAD was not 
significant. Therefore, the Western based prostate 
cancer risk calculators are not useful for urologists 
in predicting prostate cancer in the Korean 
population.3 It seems that PCa in Korean men 
exhibit poor differentiation regardless of the initial 
serum PSA level or clinical stage at presentation 
unlike Western population. This may be due to 
smaller PV of an Asian population, which was 
suggested by another study. This may be due to 
the difference between the populations, on which 
the calculators were based.17 External validations 
of the objectivity of nomograms are important to 
confirm the performance of these tests because 
they are often useful only for the cohorts from 
which they were developed. In addition, there is 
a limited efficacy of nomograms when externally 
validated with other study cohorts.
From the logistic regression analysis as a 
model for IPCRC, there were some differences 
compared to other risk calculator. Coefficient for 
PSA in IPCRC was 0.62 lower than ERSPC, of 
1.1 and PCPT 0.85. it was similar with prostate 
volume of 0.04 in IPCRC lower than ERSPC of 
1.36. But IPCRC had higher coefficient in DRE 
findings of 3.99 than ERSPC of 0.8 and PCPT 
0.91. The differences was due to low incidence 
of PCa in our population and most of our patients 
came in a more severe conditions and were not 
suitable for screening (e.g had urinary retention). 
The ROC analysis of IPCRC showed high 
sensitivity and specificity in predicting  prostate 
cancer with area under curve (AUC) 0.938 (95% 
CI 0.93-0.95) in our study population. The AUC 
was higher than the PCPT (AUC 0.70) and  the 
ERSPC (AUC 0.79).12 This indicated that IPCRC 
might be better in differentiating patient with 
PCa and BPH. A further validation in a larger 
population is needed to confirm this finding.
This study had several limitations. First, 
the results may have been influenced by the 
heterogenecity of patients, tumours and biopsy 
techniques. Second, this study had fewer sample 
compared to the others. Indonesian prostate 
cancer risk calculator was developed from 1957 
men in Indonesian but PCPT was developed 
from 18,882 men16,17 while ERSPC developed 
from 6,288 men.13,19 Third, we did not consider 
race as one of the predictive variable in this 
calculators because of incomplete medical data. 
Four, Family history of PCa was not account for 
its predictive. However, we believed that IPCRC 
can be useful and had a good predictive value in 
diagnosing Pca in our population.
CONCLUSION
We have developed the Indonesian Prostate 
Cancer Risk Calculator which includes age, PSA, 
DRE, and prostate volume as its variables. Future 
studies to validate this risk calculator are needed.
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